Big Chemical Encyclopedia

Chemical substances, components, reactions, process design ...

Articles Figures Tables About

Enterococcus faecium infection resistance

Vancomycin-resistant Enterococcus faecium infections For the treatment of vancomycin-resistant E. faecium infections, including cases with concurrent bacteremia. [Pg.1624]

Most appropriate use is when vancomycin-resistant Enterococcus faecium infection is documented or strongly suspected, or for oral therapy of methicillin-resistant Staphylococcus aureus infection... [Pg.700]

Linden PK, Moellering RC Jr, Wood CA, Rehm SJ, Flaherty J, Bompart F, Talbot GH Synercid Emergency-Use Study Group. Treatment of vancomycin-resistant Enterococcus faecium infections with quinupristin/dalfopristin. Clin Infect Dis 2001 33(ll) 1816-23. [Pg.3185]

Verma A, Dhawan A, Philpott-Howard J, Rela M, Heaton N, Vergani GM, Wade J. Glycopeptide-resistant Enterococcus faecium infections in paediatric liver transplant recipients safety and clinical efficacy of quinupristin/ dalfopristin. J Antimicrob Chemother 2001 47(l) 105-8. [Pg.3185]

G Saurina, D Landman, JM Quale. Activity of disinfectants against vancomycin-resistant Enterococcus faecium. Infect Control Hosp Epidemiol 18(5) 345-347, 1997. [Pg.117]

Dhawan B, Gadepalli R, Kapil A. (2009) In vitro activity of daptomycin against Staphylococcus Aureus and vancomycin-resistant Enterococcus Faecium isolates associated with skin and soft tissue infections First results from India. Diagn Microbiol Infect Dis 65 196-198. [Pg.132]

Infections due to vancomycin-resistant Enterococcus faecium IV 7 5 mg/kg/dose q8h Skin and skin-structure infections IV 7 5 mg/kg/dose q 12h. [Pg.1072]

Ostrowsky BE, Clark NC, Thauvin-Eliopoulos C, Venkataraman L, Samore MH, Tenover FC, Eliopoulos GM, Moellering RC Jr, Gold HS. A cluster of VanD vancomycin-resistant Enterococcus faecium molecular characterization and clinical epidemiology. J Infect Dis 1999 180(4) 1177-85. [Pg.3605]

Two important new streptogramins are quinu-pristin (Fig. 10.15A) and dalfopristin (Fig. 10.15B), which are derivatives of pristinamycin I and IIA, respectively. Individually, the two components are bacteristatic but in combination they act synergistically to produce a bactericidal effect by inhibiting early (dalfopristin) and late (quinupristin) phases of bacterial protein synthesis. These two antibiotics are used intravenously in combination (ratio 30 70) for the treatment of serious or life-threatening infections associated with vancomycin-resistant Enterococcus faecium bacteraemia, although the effect against this organism is bacteristatic. [Pg.169]

Till M, Wixson RL, Pertel PE. Linezolid treatment for osteomyelitis due to vancomycin-resistant Enterococcus faecium. Clin Infect Dis 2002 34 1412-1414. [Pg.2129]

Aarestrup FM, Agerso Y, Gemer-Smidt P, Madsen M, Jensen LB (2000) Comparison of antimicrobial resistance phenotypes and resistance genes in Enterococcus faecalis wnd Enterococcus faecium from humans in the community, broilers, and pigs in Denmark. Diagn Microbiol Infect Dis... [Pg.115]

A drug combination of the streptogramins, quinupristin and dalfopristin was approved for IV use in the treatment of infections caused by vancomycin-resistant Enterococcus faecium bacteremia as well as skin/skin structure infections caused by MRSAand methicillin-sensitive Streptococcus pyogenes. Certain strains of E. faecium are resistant to essentially all... [Pg.1647]

SW Frantz, KA Haines, CG Azar, JI Ward, SM Homan, RB Roberts. Chlorhexidine gluconate (CHG) activity against clinical isolates of vancomycin-resistant Enterococcus faecium (VREF) and the effects of moisturizing agents on CHG residue accumulation on the skin. J Hosp Infect 37(2) 157-164, 1997. [Pg.178]

Chong YP, Lee SO, Song EH, Lee EJ, Jang EY, Kim SH, Choi SH, Kim MN, Jeong JY, Woo JH, Kim YS. Quinupris-tin- dalfopristin versus linezolid for the treatment of vancomycin-resistant Enterococcus faecium bacteraemia efficacy and development of resistance. Scand J Infect Dis 2010 42(6-7) 491-9. [Pg.423]

Galloway-Pena JR, Nallapareddy SR, Arias CA, Eliopoulos GM, Murray BE. Analysis of clonality and antibiotic resistance among early clinical isolates oi Enterococcus faecium in the United States. J Infect Dis. 2009 200(10) 1566-73. doi 10.1086/644790. [Pg.228]

Weisser M, Oostdijk EA, Willems RJ, Bonten MJ, Frei R, Elzi L, Flalter J, Widmer AF, Top J. Dynamics of ampicillin-resistant Enterococcus faecium clones colonizing hospitalized patients data from a prospective observational study. BMC Infect Dis. 2012 12 68. doi 10.1186/1471-2334-12-68. [Pg.233]

See other pages where Enterococcus faecium infection resistance is mentioned: [Pg.113]    [Pg.1649]    [Pg.1021]    [Pg.350]    [Pg.199]    [Pg.251]    [Pg.12]    [Pg.170]    [Pg.102]    [Pg.174]    [Pg.876]    [Pg.6]    [Pg.713]    [Pg.3182]    [Pg.268]    [Pg.124]    [Pg.1564]    [Pg.126]    [Pg.371]    [Pg.28]    [Pg.1042]    [Pg.262]    [Pg.342]    [Pg.753]    [Pg.37]   
See also in sourсe #XX -- [ Pg.308 ]



SEARCH



Enterococcus

Enterococcus faecium

Enterococcus faecium infection

Infection resistance

© 2024 chempedia.info